DailyIQ
|
Sector:HealthcareAll sectors
Last updated 1 minute ago

DHR·Danaher Corporation

$.
+. (+.%)
After Hours
High
$201.00
Open
$198.70
Market Cap
140.88B
52W High
$242.80
Low
$198.00
P. Close
$198.95
P/E
38.19
52W Low
$160.93
Fwd P/E
21.65
DailyIQ Est.
$254.00
Technical Score (1D)
86
BUY
News Sentiment
68
BULLISH
Danaher’s Q1 earnings report, released 60 hours ago, highlighted robust growth in its bioprocessing business while diagnostics lagged, leaving the company’s valuation above intrinsic value. This earnings momentum underscores the need to monitor whether bioprocessing can sustain its pace and whether the diagnostics shortfall will be addressed before the next earnings cycle. Jim Cramer’s recent commentary, 66 hours ago, slammed DHR as a disappointment amid a wave of debt issuances, raising concerns that the company’s capital structure could weigh on valuation in the near term. The debt narrative dovetails with the Q1 results, as investors weigh the premium price against the company’s leverage profile and potential upside. A regulatory win for Beckman Coulter’s Access p‑Tau217 assay, announced 80 hours ago, could broaden EU market reach for diagnostics, offering a counterbalance to the current underperformance. However, the market has tempered enthusiasm, and the stock’s recent softness suggests caution about translating the CE Mark into immediate revenue growth. The biotech unit’s 7 % core revenue rise, reported 110 hours ago, confirms bioprocessing demand but also signals product‑demand volatility that could temper future earnings. Looking ahead, traders should watch the upcoming Q2 earnings release for guidance on revenue mix, margin trends, and any updates on the Masimo acquisition’s integration timeline. Additionally, monitoring the company’s debt trajectory and any capital‑allocation decisions will be key to assessing whether the premium valuation can be justified. Finally, keep an eye on regulatory developments for the new AI‑enabled wearable monitoring feature, as FDA clearances could provide a new revenue stream that may shift the earnings outlook.
Earnings Summary
Danaher Corporation (DHR) is a global manufacturer and marketer of products and services across biotechnology, life sciences, and diagnostics, operating through three key segments that supply instruments, consumables, and clinical solutions to professional, medical, and industrial customers. In the healthcare diagnostics and research sector, the company’s earnings are driven by recurring consumable sales and incremental product launches. In the most recent two quarters with data, Q1 2026 reported an EPS of $2.06 versus an estimate of $1.85656 and revenue of $5.951 billion, while Q4 2025 delivered an EPS of $2.23 versus an estimate of $2.1743 and revenue of $6.838 billion; the prior two quarters, Q3 2025 and Q2 2025, posted EPS of $1.89 and $1.80 and revenues of $6.053 billion and $5.936 billion, respectively. Danaher beat estimates in each of the last five quarters, with only Q4 2024 missing the EPS estimate, reflecting a consistent earnings beat pattern. Historically, the company has shown YoY revenue growth from $6.538 billion in Q4 2024 to $6.838 billion in Q4 2025, a 4.6 % increase, and EPS growth from $2.14 to $2.23, a 4.2 % rise, underscoring steady top‑line and profitability momentum. Recent news highlights the FDA 510(k) clearance of Masimo’s AI‑enabled respiratory‑depression detection feature on the Radius VSM platform, which expands Danaher’s pulse‑oximetry line into actionable, AI‑driven hospital monitoring and could increase recurring consumables revenue; HSBC’s price‑target cut to $230 from $270 also signals a reassessment of growth expectations. Investors should watch the July 21 earnings call for guidance on product adoption, the projected revenue impact of the new feature, and any updates on regulatory developments, as these factors will shape the company’s near‑term earnings trajectory.

EPS

EstBeatMiss
$1.56$1.75$1.94$2.13$2.32Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.84 - -
Q1'26$1.86$2.06+11.0%
Q4'25$2.17$2.23+2.6%
Q3'25$1.72$1.89+9.8%
Q2'25$1.64$1.80+9.5%
Q1'25$1.64$1.88+14.4%

Revenue

EstBeatMiss
$5.6B$5.9B$6.3B$6.7B$7.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.2B - -
Q1'26$6.1B$6.0B-2.9%
Q4'25$6.9B$6.8B-0.5%
Q3'25 - $6.1B -
Q2'25 - $5.9B -
Q1'25 - $5.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

DHR Stock Snapshot

DHR is currently trading at $199.05, giving Danaher Corporation a market cap of 140.88B and a P/E ratio of 38.2. Today's range spans $198.00–$201.00, with shares opening at $198.70 and moving up $0.10 (0.1%) from the prior close. DailyIQ's technical score sits at 86/100 (BUY) with a news sentiment reading of 68/100.

Over the past year DHR has traded between $160.93 and $242.80 - the current price is +23.7% off the 52-week low and -18.0% from the high. 34 analysts cover the stock with a Buy consensus and a mean 12-month target of $242.26 (range $200.00–$310.00), implying upside of +21.7%.

Growth-oriented Healthcare investors looking for technical confirmation find it in DHR: BUY signal, 86/100 score, bullish sentiment at 68/100, price $199.05 (in the middle of its 52-week range). The current P/E ratio stands at 38.2. The 140.88B market cap is the sweet spot - big enough to absorb institutional sizing, small enough to move materially on conviction. Annual range: $160.93–$242.80.

Earnings revision cycles in large-cap Healthcare names tend to compound: when technicals confirm a BUY thesis (86/100) and news sentiment (68/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $199.05 (in the middle of its 52-week range), DHR's position within the $160.93–$242.80 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.